For the quarter ended March 31, 2025, Edesa reported a net loss of $1.6 million, or $0.30 per common share, compared to a net ...

RNA-1083 vaccine is noninferior and induces higher immune responses than recommended influenza and COVID-19 vaccines.

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Presentations at three ...

The Centers for Disease Control and Prevention (CDC) and seven US pediatric medical centers report a notable association ...

THE Covid‐19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has represented a paramount global ...

Of the RSV patients aged 60 or older, 23.0% were admitted to an ICU, 31.5% had acute organ failure, and 9.8% received IMV or ...

Kochi: A study based on surveillance data from 17 virus research labs in India found that Nipah virus (NiV) outbreaks in ...

A Spanish study found that nirsevimab prophylaxis significantly reduced infant hospitalizations, ICU admissions, and severe ...

A nationally representative U.S. study of over 100,000 adults found that post-COVID conditions (PCCs) significantly reduce ...